SLC5A2 and early-onset autosomal dominant Alzheimer disease: SGLT2 inhibitors may assist patients with Alzheimer’s disease due to their direct neuroprotective effects, such as BDNF increase and AChE inhibition, as well as anti-inflammatory, anti-oxidative, or atheroprotective effects [256].